LABORATORIO REIG JOFRE, S.A. REIG JOFRE sales held steady in the second quarter of 2021 with 3% growth in its EBITDA
Reig Jofre managed to maintain its revenue figure compared to the first half of 2020, when sales were driven by essential medicines linked to COVID-19.
At the end of the first half, sales exceeded €116 million, a figure in line with the same period of the previous year. Some product ranges achieved growth in this context, which offset the impacts of lower demand for antibiotics and OTC products as a result of social distancing measures. EBITDA grew by 3%, reaching €13.3 million, which enabled consolidation of profitability on sales of this magnitude exceeding 11%.
The Pharmaceutical Technologies division, which mostly manufactures and sells products for hospital use, had a decrease in their revenue, while the Speciality Pharmacare division, which produces prescription medical products, was already showing clear signs of recovery. With clear growth in the second quarter, Consumer Healthcare was able to reverse the first quarter's trend and achieved a higher revenue figure than that of 2020.
Download the full document (PDF)
Attachments
- Original document
- Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 29 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2021 07:16:10 UTC.
